Bordetella Pertussis Fimbriae 2/3 Vaccine, Inactivated
This is an inactivated vaccine targeting the fimbriae 2 and 3 proteins of Bordetella pertussis, the bacterium responsible for whooping cough (pertussis). It is designed to induce immune protection against pertussis, typically as part of combination vaccines that may include diphtheria and tetanus components. This type of vaccine antigen is primarily used in pediatric immunization programs.
An inactivated vaccine component providing immunity against Bordetella pertussis fimbriae antigens to prevent whooping cough.
Key facts at a glance
- RxNorm
- 1300182
- Generic
- Bordetella Pertussis Fimbriae 2/3 Vaccine, Inactivated
- Class
- pin-variant
- Brands
- Quadracel, Vaxelis, Daptacel, Adacel
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 0.5mL single dose
- Maximum
- consult physician
- Frequency
- booster every 10 years
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.5mL per dose
- Maximum
- consult physician
- Frequency
- 5-dose series at 2, 4, 6, 15-18 months, and 4-6 years
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.5mL single dose
- Maximum
- consult physician
- Frequency
- one-time booster
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
7 groupspregnancy
second third trimesterstandard_dose
Tdap vaccine recommended during every pregnancy, preferably at 27-36 weeks gestation to maximize antibody transfer to fetus
standard prenatal care
pregnancy
first trimesterstandard_dose
vaccination may be considered if high risk of exposure, otherwise defer until second trimester if possible
standard prenatal care
Use with caution and monitor for adverse effects.
lactation
breastfeedingno_adjustment
can be administered during lactation without interruption of breastfeeding
none
pediatric_age
infants 2 months to 6 yearsage_appropriate_formulation
DTaP series recommended at 2, 4, 6, 15-18 months and 4-6 years; minimum interval 4 weeks between doses
standard pediatric well-child visits
geriatric
65 years and olderstandard_dose
one-time Tdap booster if not previously received;Td booster every 10 years
standard pre-vaccination assessment
renal_impairment
severe ckd less than 30standard_dose
can be administered without dose adjustment; patients on dialysis may have reduced immune response
standard pre-vaccination screening
hepatic_impairment
moderate to severestandard_dose
can be administered without dose adjustment
standard pre-vaccination screening
Statistics and clinical data
Commonly prescribed since
General prescribing information for pertussis-containing vaccines
Drug class
Vaccine classification information
Common uses
Primary therapeutic indication
Vaccine efficacy
Estimated protective efficacy against pertussis disease
Prevention of pertussis (whooping cough) caused by Bordetella pertussis infection. Often included as a component in combination vaccines such as DTaP for children or Tdap for adolescents and adults.
The vaccine contains inactivated fimbriae 2 and 3 antigens from B. pertussis, which are filamentous proteins on the bacterial surface. These antigens stimulate the immune system to produce antibodies that help neutralize the bacterium and prevent colonization of the respiratory tract.
This vaccine is typically administered as part of combination formulations rather than as a standalone product. Like all pertussis vaccines, it does not provide 100% protection and waning immunity may occur over time. Contraindications include severe allergic reactions to previous doses.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy